MedicaidPrior AuthLow impact
Istodax (romidepsin) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Mar 1, 2026
We identified it
Jun 24, 2026
Summary
Humana has established a new prior authorization policy for Istodax (romidepsin) for Indiana Medicaid patients with cutaneous T-cell lymphoma. The medication requires prior authorization and must meet specific criteria including either being used as primary biologic systemic therapy or the patient having received at least one prior therapy.
Action Required
Before March 1, 2026: Billing team must implement prior authorization requirements for Istodax (romidepsin) for Indiana Medicaid patients with cutaneous T-cell lymphoma. Update billing system to flag these cases and ensure providers obtain prior auth by documenting that the medication is either primary biologic systemic therapy OR patient has received at least one prior therapy. Claims will be denied without proper prior authorization.